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Clues from Alopecia Areata on 
the Role of Neuropeptides in the 
Initiation of Autoimmunity
Richard S. Kalish1
A fascinating question regarding the pathogenesis of alopecia areata is the 
potential linkage with the brain. Siebenharr et al. demonstrate that substance 
P fibers are increased in early lesions, and that substance P treatment induces 
catagen follicles along with activated CD8+ T cells. Potentially, neuropeptides 
serve as the initial insult resulting in loss of tolerance and autoimmune disease.
Journal of Investigative Dermatology (2007) 127, 1289–1291. doi:10.1038/sj.jid.5700655
In this issue of the Journal of Investigative 
Dermatology, Siebenharr et al. (2007) 
present data strongly suggesting a role 
for substance P in alopecia areata. This 
is of great interest because it provides a 
potential link between brain and body 
with respect to the initiation of autoim-
mune disease. There is considerable 
evidence supporting an autoimmune 
pathogenesis for alopecia areata (Gilhar 
and Kalish, 2006). Alopecia areata has 
a statistical association with autoim-
mune thyroiditis and HLA DQB1*03. 
Histologically, the condition is marked 
by an infiltrate of lymphocytes around 
hair follicles, associated with prema-
ture catagen, and conversion of termi-
nal hairs to miniature anagen hairs. The 
hair follicle demonstrates evidence of 
immune activation including expression 
of major histocompatibility complex 
(MHC) class I and class II molecules as 
well as ICAM-1 on follicular epithelium, 
where these molecules are usually poor-
ly expressed or absent. The T-cell infil-
trate is characterized by perifollicular 
CD4+ cells and intrafollicular CD8+ cells 
as well as a T-helper 1 cytokine profile. 
Immunologic intervention such as treat-
ment with allergic contact sensitizers 
can induce hair regrowth, supporting a 
role of immunology in the pathogenesis.
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 Substance P-containing 
nerve fi bers are greatly 
elevated in early lesions, 
and reduced in late 
lesions.
Evidence for a role for T cells in the 
pathogenesis of alopecia areata is pro-
vided by the ability to transfer hair loss 
to human scalp grafts on severe com-
bined immunodeficient (SCID) mice 
by injection of activated T cells derived 
from alopecia areata lesions (Gilhar et 
al., 1998). The T cells must first be acti-
vated with hair follicle autoantigen to 
induce hair loss. Cooperation between 
CD4+ and CD8+ T cells is required for 
maximal hair loss. Melanocyte-derived 
peptides are capable of serving as auto-
antigens for inducing alopecia areata in 
this transfer system.
Murine alopecia areata is a well-char-
acterized system that shares many his-
tologic and immunologic features with 
the human condition (McElwee et al., 
1998). Female C3H/HeJ mice develop 
spontaneous alopecia areata with age at 
a rate of approximately 20% by 1 year. 
The immunohistologic features are simi-
lar to human disease, with perifollicular 
CD4+ cells, intrafollicular CD8+ cells, 
and expression of MHC class I and class 
II and ICAM-1 on follicular epithelium. It 
is possible to transfer hair loss to young 
C3H/HeJ mice by grafting involved skin. 
It is presumed that passenger lympho-
cytes in the skin mediate the transfer.
Alopecia areata provides an excel-
lent model to study the initiation of 
autoimmunity. The proximal (“lower”) 
hair follicle epithelium is deficient in 
expression of MHC class I and class II 
as well as numbers of dendritic anti-
gen-presenting cells, rendering the hair 
follicle an immune-privileged site (Ito 
et al., 2004). Additional mediators of 
immune privilege in the hair follicle 
include immunosuppressive cytokines 
(for example, transforming growth 
factor-α and α-melanocyte-stimulat-
ing hormone). As is noted above, with 
active disease, immune privilege is lost 
and the hair follicle epithelium express-
es MHC class I and class II and ICAM-1 
along dendritic antigen-presenting cells. 
Paus et al. (1993) have hypothesized 
that this loss of immune privilege is 
key to the induction of alopecia areata. 
Their proposal was tested by induction 
of hair follicle MHC class I and class II 
expression in C3H/HeJ mice by injec-
tion of IFN-γ. The mice developed alo-
pecia areata at a significantly higher rate 
and at a younger age than their control 
mice injected with saline (Gilhar et al., 
2005). Only genetically susceptible 
C3H/HeJ mice could be induced to lose 
hair by this treatment. Clinically rel-
evant factors that may induce initial loss 
of immune privilege remain to be deter-
mined. It is unlikely that IFN-γ plays this 
initial role, because the primary source 
for this cytokine is activated T cells, and 
it would be difficult to postulate T-cell 
activation prior to loss of immune privi-
lege. Neuropeptides and neurogenic 
inflammation have been proposed as a 
potential initial insult capable of trigger-
ing autoimmunity in a genetically sus-
ceptible host.
Many patients report that their initial 
episode of alopecia areata was induced 
by a specific stressful event. Although 
this finding has not been confirmed by 
population-based epidemiologic stud-
ies, experienced clinicians hear this his-
tory repeatedly. This intriguing story has 
fueled attempts to link autoimmunity 
with the brain. Immunomodulatory neu-
ropeptides associated with alopecia area-
ta include substance P and calcitonin 
gene-related peptide (CGRP) (Rossi et al., 
1997; Meyronet et al., 2003; Botchkarev 
et al., 2006). CGRP released from cuta-
neous nerves can induce mast-cell 
degranulation, with release of immuno-
suppressive tumor necrosis factor-α and 
IL-10. CGRP-containing neurons come 
in close proximity to Langerhans cells, 
and Langerhans-cell antigen-present-
ing function is inhibited by CGRP treat-
ment. In addition, CGRP interacts with 
keratinocyte factors to promote melani-
zation. Involved scalp has reduced cuta-
neous levels of CGRP, and serum levels 
of CGRP are depressed to about half of 
control values in patients with active 
alopecia areata. CGRP is also a potent 
inducer of vasodilatation of skin vascula-
ture, which may be of significance to the 
hair cycle. The literature on substance P 
had been contradictory until clarified by 
the study of Siebenharr et al. (2007).
The key to understanding the role 
of substance P in alopecia areata is the 
demonstration by Siebenharr et al. (2007) 
that substance P-containing nerve fibers 
are greatly elevated in early lesions, 
and reduced in late lesions. Advanced 
lesions also expressed increased levels 
of the substance P-degrading enzyme 
neutral endopeptidase. Injection of sub-
stance P-treated agarose beads induced 
catagen hair follicles as well as mast-cell 
degranulation. Substance P treatment 
resulted in a modest accumulation of 
CD8+ T cells along with an impressive 
increase in granzyme expression by 
these CD8+ cells. Granzyme B is both 
a marker of CD8+-cell activation and 
an important effector molecule of pos-
sible relevance to alopecia areata patho-
genesis. Neurokinin-1 receptors were 
expressed on CD8+ cells and mono-
cytes, but not on mast cells. CD8+ cells 
infiltrating the follicular epithelium were 
found to express both neurokinin-1 and 
granzyme B.
The significance of this study is that 
it demonstrates that: 
(1)  Substance P-containing neurons 
are increased in early lesions of 
alopecia areata.
(2)  Substance P treatment induces 
catagen hair follicles.
(3)  Substance P treatment results 
in recruitment of intrafollicular 
CD8+ cells expressing the effector 
molecule granzyme B as well as 
neurokinin-1 receptors.
The data suggest that substance P 
acts through immune activation of 
CD8+ cells. Intrafollicular granzyme 
B-positive CD8+ cells are a feature of 
alopecia areata. However, it is neces-
sary to determine whether substance 
P induces catagen in immunodeficient 
or CD8 knockout mice. The authors 
reference data that substance P induc-
es catagen in mouse strains not sus-
ceptible to alopecia areata. This raises 
questions regarding the nature of the 
genetic susceptibility to alopecia area-
ta. Perhaps the limiting factor is the 
ability to develop a self-perpetuating 
CD8+ immune response after initial 
insult with substance P.
It is proposed that autoimmunity is 
induced by a loss of self-tolerance. In the 
case of immune-privileged sites, such as 
the hair follicle, loss of tolerance may 
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result from loss of immune privilege. 
Possible causes of such loss of immune 
privilege include infections, and trauma 
(for example, in the eye). However, data 
are now accumulating that suggest that 
neuropeptides may initiate autoimmuni-
ty. The study by Siebenharr et al. (2007) 
suggests that substance P may play 
such a role in initiating alopecia area-
ta. It is probable that the ability of the 
autoimmune process to establish itself 
and propagate after the initial insult is 
governed by genetic factors.
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